Quasar Medical has acquired Medres International’s Nitinol Design and Development Center in San Diego, adding specialist engineering and manufacturing capability for minimally invasive medical devices.
The transaction includes a 10,000 sq ft facility established in 2024, together with its dedicated nitinol operation, engineering team, production equipment, and customer work. Medres will continue operating its remaining business independently, while Quasar assumes responsibility for the San Diego nitinol business and its customers.
Financial terms were not disclosed. The industrial value lies in the capability being absorbed into Quasar’s network rather than the size of the site alone. Nitinol components are often small, but their manufacture depends on tightly controlled material preparation, thermal processing, forming, cutting, surface treatment, inspection, and validation.
The nickel-titanium alloy is used where designers need controlled shape recovery, superelastic behaviour, or repeated deformation in compact devices. That makes it useful in stents, guidewires, retrieval systems, implants, catheter assemblies, and other minimally invasive products, while giving process engineering an unusually direct influence over final device performance.
Quasar said the San Diego centre will support advanced design, prototyping, process optimisation, and precision manufacturing. Its disclosed capabilities include laser cutting, shape setting, and electropolishing, giving the company greater control over the route from initial geometry through heat treatment and surface finishing.
The acquisition also links early development more closely with commercial production. The San Diego centre is about an hour from Quasar’s manufacturing operation in Tecate, Mexico, creating a comparatively short route between design work, process development, validation, and higher-volume manufacture.
That distance matters because transferring a medical device from development to production often exposes assumptions that were manageable at prototype scale but unstable in repeatable manufacture. Tooling, fixturing, heat-treatment cycles, dimensional tolerances, surface condition, inspection methods, and operator handling must all be converted into controlled instructions before a product can move beyond engineering builds.
Quasar intends to integrate the San Diego team with development centres in Israel and Galway, as well as its wider manufacturing network. The company operates 11 locations and employs about 5,000 people, with existing capabilities covering complex catheters, medical balloons, steerable systems, electromagnetic sensors, and assemblies.
Adding nitinol expertise broadens the range of programmes it can take from concept to validated production without handing critical stages to separate suppliers. Fewer interfaces can simplify technical responsibility and change control, although the benefit will depend on how effectively engineering knowledge is transferred between locations and embedded in the group’s quality system.
The San Diego operation will serve as a design and development hub rather than merely an acquired production line. Quasar is taking on specialist personnel as well as equipment, including experienced advisers and engineering leadership. Retaining that knowledge matters because nitinol processing often depends on accumulated practical understanding alongside formal specifications.
Medical-device contract manufacturers have been moving further upstream as customers seek earlier design support and a more direct route into regulated production. A supplier involved during development can shape processes, inspection strategies, and production records around the eventual manufacturing requirement instead of trying to industrialise a finished concept after the important decisions have already been made.
The model is not without risk. Integrating a newly acquired technical centre across several countries requires common documentation, compatible equipment strategies, clear ownership of design decisions, and disciplined customer communication. Quasar must also show that development speed does not come at the expense of traceability or validation depth.
The company’s network operates under ISO 13485 certification, but certification is only the baseline for the acquired capability. Customers will look for evidence that laser cutting, shape setting, electropolishing, and related operations can be qualified consistently, transferred where necessary, and scaled without altering the material characteristics on which a device depends.
The acquisition gives Quasar a more complete technical proposition in a material that sits close to the performance limits of many minimally invasive products. The next measure will be operational: whether the San Diego centre can reduce development hand-offs, shorten validation cycles, and feed stable work into Tecate and the wider network.
A 10,000 sq ft site will not transform the medical-device supply chain by itself. It can become disproportionately valuable when the processes inside it determine whether a complex product remains a prototype or becomes a repeatable, regulated manufacturing programme. That value will depend on disciplined integration rather than acquisition arithmetic.
